Cardiovascular Safety Communications After US Food and Drug Administration Approval of Contemporary Cancer Therapies.
prospective_cohort · Level II
Where this comes from
- Record sourced from PubMed, PMID 34591072.
- Also identified by DOI 10.1001/jamaoncol.2021.4771 and PMC identifier 8485208.
- No licence information is recorded for this record.
- Because redistribution is not established, this page shows the abstract only. Follow the links below for the full text.
Abstract
This cohort study examines the prevalence and factors associated with postmarketing communications by the US Food and Drug Administration about cardiovascular events associated with anticancer thearpy.
Medical subject headings
- Drug Approval
- Neoplasms